• Olaparib: Metabolic Control of PARP Sensitivity

  2026-08-31

  Olaparib and AZD2281 research is expanding beyond BRCA status toward metabolic control of homologous recombination. This article explains how the αKG–TMLHE–carnitine axis can shape PARP inhibitor response and improve DNA damage response assay design.

• ABT-737: Reading Mitochondrial Death Signals

  2026-08-30

  ABT-737 is a BCL-2 protein inhibitor that can expose how cancer cells balance mitochondrial apoptosis against organelle quality control. This guide connects apoptosis induction in cancer cells with assay design lessons from Parkin-mediated mitophagy research, offering a distinct framework for interpreting mitochondrial readouts.

• Linoleic Acid (C18:2): Practical Assay Guide

  2026-08-29

  Linoleic Acid (SKU C3108) provides a defined C18:2(9Z,12Z) lipid input for membrane, oxidative stress, erythrocyte, epithelial migration, and essential fatty acid studies. It is water-insoluble, requires compatible solvent handling, and is best used with freshly prepared solutions rather than long-term aqueous stocks.

• Cyanine 5-dCTP for Fluorescent DNA Workflows

  2026-08-28

  Cyanine 5-dCTP enables direct red-fluorescent labeling during enzymatic DNA synthesis, PCR development, and DNA fluorescent probe synthesis. This guide connects practical Cy5-dCTP assay design with a 2025 DNA-framework study, emphasizing controlled incorporation, quantitative controls, and troubleshooting.

• FCCP for HIF and Mitochondrial Biology

  2026-08-28

  FCCP converts mitochondrial proton-gradient dissipation into measurable changes in oxygen consumption, ATP production, and HIF-associated signaling. This guide separates acute bioenergetic profiling from longer cancer-cell treatments and shows how the compound can support hypothesis-driven studies of tumor-associated macrophage metabolism.

• hUC-MSCs Relieve PND via STMN2/NMNAT2-SARM1

  2026-08-27

  This study identifies a β-NGF-dependent STMN2/NMNAT2–SARM1–NF-κB pathway through which human umbilical cord mesenchymal stem cells improve postoperative cognitive impairment in aged mice. Its combination of behavioral, pathological, proteomic, and causal perturbation experiments provides a mechanistic framework for developing cell-based interventions for perioperative neurocognitive disorders.

• MiR-519d-3p, Exosomes, and Preeclampsia

  2026-08-27

  A 2025 study connects placenta-derived exosomal miR-519d-3p with altered T-cell behavior relevant to preeclampsia. Its combined sequencing and in vitro immune-cell model indicates that this cargo can promote Jurkat T-cell proliferation, suppress apoptosis, and favor Th17 differentiation, providing a mechanistic framework for studying disrupted maternal–fetal immune tolerance.

• AM 281 in TBI: From CB1 to GLT-1

  2026-08-26

  AM 281 is a selective CB1 cannabinoid receptor antagonist that can function as a causal probe in traumatic brain injury research. This article explains how to connect CB1-CREB signaling, astrocytic GLT-1 regulation, glutamate excitotoxicity, and cognitive assays without confusing mechanistic evidence with therapeutic claims.

• NSC-23766 Rac GTPase Inhibitor Workflows

  2026-08-26

  Build reproducible Rac1 experiments with NSC-23766 across breast cancer, apoptosis, cell-cycle, and endothelial-barrier models. This guide connects concentration planning, orthogonal readouts, combination studies, and troubleshooting to evidence from product data and a breast cancer co-targeting study.

• Cell Death in Liver Disease: Mechanisms

  2026-08-25

  Luedde, Kaplowitz, and Schwabe synthesize how apoptosis, necrosis, and necroptosis generate distinct inflammatory and fibrogenic responses across liver diseases. The review’s practical contribution is to connect cell-death mechanisms with biomarkers, disease progression, hepatocellular carcinoma, and the prospects and limits of pathway-directed intervention.

• E-64: Mechanism and Cysteine Protease Inhibition

  2026-08-25

  E-64 is an irreversible L-trans-epoxysuccinyl peptide used for cysteine protease inhibition and cathepsin activity studies. Its broad active-site reactivity supports mechanistic assays, but it does not identify one protease or establish a specific cell-death pathway by itself.

• Class II Olfactory Receptors and Fatty Acid Odors

  2026-08-24

  A 2026 Cell study uses cryo-EM structures to explain how the class II olfactory receptor Olfr110 recognizes unsaturated fatty acid metabolites through a large, chemically diverse binding pocket. The work identifies conserved recognition motifs, an inward-moving extracellular loop, and an activation pathway distinct from canonical class A GPCRs, providing a structural framework for studying odorant receptor biology and receptor-directed pharmacology.

• IWP-L6 as a Causal Wnt Signaling Probe

  2026-08-24

  IWP-L6 is a sub-nanomolar Porcupine inhibitor for dissecting how Wnt ligand processing controls developmental and metabolic phenotypes. This article presents an assay-first framework linking Porcn inhibition to Wnt-dependent O-GlcNAcylation, glycolysis, osteogenesis, and tissue morphogenesis.

• How Dual-Action Inhibitors Rewire p38α Dephosphorylation

  2026-08-23

  The reference preprint shows that kinase inhibitors can do more than occupy the p38α active site: selected compounds also expose the activation-loop phosphothreonine to the WIP1 phosphatase. Structural and biochemical evidence supports a conformation-directed strategy that may improve control of kinase signaling, while also defining important limits for translating the findings into cytokine or disease models.

• Anisomycin: Designing JNK Signaling Assays

  2026-08-22

  Anisomycin is a powerful JNK agonist for dissecting stress signaling, apoptosis, and pathway causality. This article connects its assay value to new findings on neuroligin 1 proteolysis and social memory maintenance while emphasizing experimental controls and interpretation.

622 records 1/42 page Next 12345 下5页 Last page